Amicus
Amicus Therapeutics, often referred to simply as Amicus, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2002, Amicus has established itself as a leader in the development of innovative therapies for rare and orphan diseases, particularly in the field of enzyme replacement therapy. With a strong focus on advancing treatments for conditions such as Fabry disease and Pompe disease, Amicus is recognised for its unique approach to drug development, utilising cutting-edge technology and patient-centric strategies. The company has achieved significant milestones, including the successful launch of its flagship product, which has positioned it favourably within the competitive biopharmaceutical landscape. Amicus continues to expand its operational reach, with a commitment to improving the lives of patients worldwide through its specialised therapies and robust research initiatives.
DitchCarbon Score
How does Amicus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amicus's score of 26 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amicus's reported carbon emissions
In 2020, Amicus Therapeutics, headquartered in the US, reported total carbon emissions of approximately 302,400 kg CO2e. This figure represents the company's overall emissions but does not specify the breakdown into Scope 1, 2, or 3 emissions, as no detailed scope data has been disclosed. Currently, Amicus has not set any specific reduction targets or initiatives, nor are there any commitments to the Science Based Targets initiative (SBTi) or other climate pledges. The absence of reduction targets indicates a potential area for future development in their climate strategy. As of now, Amicus's emissions data is not cascaded from any parent or related organization, indicating that the reported figures are solely from Amicus Therapeutics, Inc. The company may benefit from establishing clear climate commitments and reduction strategies to enhance its sustainability profile in the pharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amicus is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
